Abstract Background: Despite advances in treatments, 30% to 50% of stage III-IV head and neck squamous cell carcinoma (HNSCC) patients relapse within 2 years after treatment. The Big Data to Decide (BD2Decide) project aimed to build a database for prognostic prediction modeling. Methods: Stage III-IV HNSCC patients with locoregionally advanced HNSCC treated with curative intent (1537) were included. Whole transcriptomics and radiomics analyses were performed using pretreatment tumor samples and computed tomography/magnetic resonance imaging scans, respectively. Results: The entire cohort was composed of 71% male (1097)and 29% female (440): oral cavity (429, 28%), oropharynx (624, 41%), larynx (314, 20%), and hypopharynx (170, 11%); median follow-up 50.5 months. Transcriptomics and imaging data were available for 1284 (83%) and 1239 (80%) cases, respectively; 1047 (68%) patients shared both. Conclusions: This annotated database represents the HNSCC largest available repository and will enable to develop/validate a decision support system integrating multiscale data to explore through classical and machine learning models their prognostic role.
Development of a multiomics database for personalized prognostic forecasting in head and neck cancer: The Big Data to Decide EU Project / Cavalieri, S., De Cecco, L., Brakenhoff, R.H., Serafini, M.S., Canevari, S., Rossi, S., Lanfranco, D., Hoebers, F.J.P., Wesseling, F.W.R., Keek, S., Scheckenbach, K., Mattavelli, D., Hoffmann, T., López Pérez, L., Fico, G., Bologna, M., Nauta, I., Leemans, C.R., Trama, A., Klausch, T., et al.. - In: HEAD & NECK. - ISSN 1043-3074. - 43:2(2020), pp. 601-612. [10.1002/hed.26515]
Development of a multiomics database for personalized prognostic forecasting in head and neck cancer: The Big Data to Decide EU Project
Rossi, Silvia
Investigation
;Lanfranco, Davide
Investigation
;Poli, Tito
Investigation
;
2020-01-01
Abstract
Abstract Background: Despite advances in treatments, 30% to 50% of stage III-IV head and neck squamous cell carcinoma (HNSCC) patients relapse within 2 years after treatment. The Big Data to Decide (BD2Decide) project aimed to build a database for prognostic prediction modeling. Methods: Stage III-IV HNSCC patients with locoregionally advanced HNSCC treated with curative intent (1537) were included. Whole transcriptomics and radiomics analyses were performed using pretreatment tumor samples and computed tomography/magnetic resonance imaging scans, respectively. Results: The entire cohort was composed of 71% male (1097)and 29% female (440): oral cavity (429, 28%), oropharynx (624, 41%), larynx (314, 20%), and hypopharynx (170, 11%); median follow-up 50.5 months. Transcriptomics and imaging data were available for 1284 (83%) and 1239 (80%) cases, respectively; 1047 (68%) patients shared both. Conclusions: This annotated database represents the HNSCC largest available repository and will enable to develop/validate a decision support system integrating multiscale data to explore through classical and machine learning models their prognostic role.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
